Results reported for Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis. Company plans to meet with the FDA to ...

XTMAB-16 is an anti-TNFa monoclonal antibody currently under investigation. Based on its ability to block TNFa, XTMAB-16 may disrupt an inflammatory pathway and help slow granuloma formation. XTMAB16 ...

The study did not meet the primary endpoint of change from baseline in mean daily oral corticosteroid dose at week 48. Topline data were announced from a phase 3 trial evaluating efzofitimod in ...

NEW YORK & BASEL, Switzerland--(BUSINESS WIRE)--Kinevant Sciences, a clinical-stage biopharmaceutical company developing new medicines for rare autoimmune and inflammatory diseases, today announced ...

Pulmonary Sarcoidosis Efzofitimod is a potential first-in-class selective modulator of neuropilin-2 that is designed to downregulate innate and adaptive immune responses in inflammatory disease states ...

(RTTNews) - aTyr Pharma, Inc. (ATYR), a clinical-stage biotechnology company, on Wednesday announced that it will present three important posters on efzofitimod at the American Thoracic Society or ATS ...

SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of ...

Please provide your email address to receive an email when new articles are posted on . The restriction phenotype, typically associated with sarcoidosis, was only found in 47% of patients with ...

BASEL, Switzerland & LONDON & NEW YORK--(BUSINESS WIRE)--Roivant (Nasdaq: ROIV) and Kinevant Sciences, a clinical-stage biopharmaceutical company developing new medicines for rare inflammatory and ...

CHICAGO, Sept. 17, 2025 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR) expresses both solidarity and resolve as aTyr Pharma announced that its Phase 3 trial of efzofitimod in ...

Please provide your email address to receive an email when new articles are posted on . A new review published in JAMA highlights the current diagnosis and treatment of pulmonary sarcoidosis. The ...

Good breathing is at the heart of good health. When asthma or shortness of breath appears, a person might be sent for pulmonary function tests. Arlene Dunlap of Piscataway, N.J. knows those tests well ...